Podcasts about bharat biotech

From debunking myths about the Human Metapneumovirus (HMPV) to highlighting the importance of decentralized surveillance systems and rapid vaccine development, host Vikas Dandekar talks to Dr. Rajeev Jayadevan, Chairman, Research Cell, Kerala State IMA, Dr. Vinod Scaria, Chief Data Officer, Karkinos Healthcare, and Dr. Raches Ella, Chief Development Officer (Cdo), Bharat Biotech. They discuss the evolving landscape of viral outbreaks, greater pandemic preparedness, and the need for vaccine innovations. Credits: CNNNews, Firstpost, WION, IndiaTodayYou can follow Vikas Dandekar on his Linkedin, Twitter profiles and read his Newspaper Articles. Check out other interesting episodes like: Should we re-examine India’s ‘Growth Story’?, The 2024 Gold Rush, What Will Bitcoin 100k Mean For Indian investors?, Need For Speed To Fill The Skills ______, and more! You can follow Anirban Chowdhury on his social media: Twitter and Linkedin Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube. See omnystudio.com/listener for privacy information.

Welcome to Top of the Morning by Mint, your weekday newscast that brings you five major stories from the world of business. It's Tuesday, May 21, 2024. My name is Nelson John. Let's get started.No stock market updates from us today as the markets remained shut on Monday as Mumbai went to the polls.Yesterday, Iran's interior minister confirmed that the country's leader, Ebrahim Raisi, had died in a helicopter crash that also killed the country's foreign minister. We invited Elizabeth Roche, an associate professor at Jindal University, to write about the implications of this tragedy. Roche also answers what's next for Iran, and how this will affect India, the Middle East, and the West.A couple of weeks ago, a research paper by Banaras Hindu University sparked widespread worries among Indians. The paper said a significant number of people faced adverse side-effects after taking Covaxin, the indigenously developed covid vaccine. Bharat Biotech, which developed the vaccine, brushed off the concerns, pointing to other studies that proved the vaccine's safety record. Now, the government is stepping in to dismiss any concerns: the Indian Council of Medical Sciences said that BHU's study was poorly designed, and had no control group of unvaccinated individuals to compare with. Priyanka Sharma writes that the participants were contacted by telephone, and no physical examination was conducted. This ought to put Covaxin users at ease.The Reserve Bank of India has reprimanded a host of financial entities lately, from Paytm to Kotak Mahindra Bank and Bank of Baroda. Under governor Shaktikanta Das, the banking regulator is doing its best to whip every lender into shape. Prior to Das, Raghuram Rajan was at the helm. His goal was cleaning up banks' balance sheets, while Das wants to ensure better governance. But as Shayan Ghosh writes, the way the RBI has been going about this is interesting: it is now not afraid of taking big decisions. Earlier, the central bank relied on fines and warnings. Today, it is cancelling banking licences and preventing companies from taking on new customers — essentially hurting the core of their business. Shayan takes a deep dive into the RBI's practices, and why it's resorting to such measures to protect citizens.If you go to buy an electric vehicle, you'll realise that one big advantage EVs have over their fossil fuel-counterparts is that they don't carry any road tax. For example, in Karnataka, the road tax for petrol cars can be up to 17 percent of the car's price. This is an incentive from the government for companies and buyers to go green. But you don't have to electrify yourself fully to get discounts from the government. Take for example, ethanol-powered cars. Alisha Sachdev reports that union road minister Nitin Gadkari expressed interest in lowering the taxes on ethanol and ethanol-blend cars from anywhere between 2 and 14 percent. This would significantly lower the cost of cars that use either pure ethanol or a blend of ethanol and petrol, called flex-fuel cars. While flex-fuel cars aren't yet produced in India, Gadkari claims they pollute even less than EVs. In the battle between electric and petrol, ethanol seems to have gained the political upper hand.It's a good time to be a premium D2C company. Brands such as bespoke apparel maker Bombay Shirt Company, luggage maker Mokobara, and organic dairy startup Akshay Kalpa have raised funds from some of India's largest venture capital firms in the recent past. Sowmya Ramasubramanian speaks to investors who are bullish on this segment, as they see an increasing number of people willing to pay premium prices. Convenience plays a role, too. Sowmya writes that these products are more likely to be available on quick commerce apps than legacy brands. She also writes about the reality of affluent consumers, and how big an audience such brands can actually target.We'd love to hear your feedback on this podcast. Let us know by writing to us at feedback@livemint.com. You may send us feedback, tips or anything that you feel we should be covering from your vantage point in the world of business and finance.Show notes:India's ties with Iran: What after Ebrahim Raisi?Govt rejects Indian study about Covaxin side-effects In EV vs hybrid battle, flex fuel vehicles win political favourNo carrot, only stick: Why the RBI has gone beyond moral suasion and fines  VCs chase a pot of gold as India's growing affluent class goes premium 

This is the Catch Up on 3 Things for the Indian Express and I'm Flora Swain.It's the 20th of May and here are today's headlines.Polling is underway for 49 Lok Sabha seats across six states and two Union Territories including Jammu and Kashmir's Baramulla. As of this afternoon, the Election Commission received about 1036 complaints from various political parties in West Bengal related to malfunctioning EVMs, agents being stopped from entering polling booths, and voters being threatened or stopped from going to cast their votes in different constituencies.  Meanwhile, in addition to five Lok Sabha seats in Odisha, voters will also cast their ballot for the second phase of simultaneous state assembly elections in 35 seats today.Prime Minister Narendra Modi today said that he was hurt seeing the poverty in Odisha despite the state having “so many mineral resources”, and alleged that the Chief Minister's Office and residence had been captured by “a handful of corrupt people”. In an indirect dig at V K Pandian, Chief Minister Naveen Patnaik's close aide and BJD's key election strategist who is from Tamil Nadu, Modi also claimed that people were saying the keys of the Puri Jagannath Temple's Ratna Bhandar (treasure trove) had been sent to the souther state. THis is his third visit to Odisha in a fortnight.Days after a Banaras Hindu University study reported long-term adverse events of “special interest” in a group of over 900 people a year after they were vaccinated with Bharat Biotech's Covaxin, the Indian Council of Medical Research (ICMR) has called it a “poorly designed study” with critical flaws. The director-general of the apex medical research body has also written to the authors of the paper and the editor of the journal in which it was published, stating that it “incorrectly and misleadingly” acknowledges ICMR though the body did not offer any financial or technical support for the paper.The Enforcement Directorate has moved an application seeking an extension of Delhi CM Arvind Kejriwal's judicial custody by 14 days in the money laundering case linked to the 'excise policy scam' after he surrenders on 2nd of June. Kejriwal is currently on interim bail till 1st of June after he was granted bail by the apex Court.Iran's President Ebrahim Raisi has been killed in a helicopter crash in the mountains to the northwest of the country, close to its borders with Armenia and Azerbaijan.The helicopter, which was also carrying Iran's Foreign Minister Hossein Amirabdollahian and the Governor of Iran's East Azerbaijan province Malek Rahmati, disappeared in dense fog on Sunday. According to Iran's Constitution, the First Vice President Mohammad Mokhber will take over as interim president.This was the Catch-Up on the 3 Things by The Indian Express.

There has been a discernible change in the narrative over the past few weeks regarding Covid-19 vaccines. From the Andrew Bridgen affair and questions in the House of Commons regarding the unusually high seasonal death rates to the publicity that came with “Novacc” Djokovic winning the Australian Open, to the sudden collapse of Thailand's Princess Bajrakitiyabha, daughter of the King, and the resulting (likely fabricated) story that Thailand is nullifying its Pfizer contracts, the powers-that-be - and I'm still not sure who they actually are - seem to have lost control of the narrative.The take-up of boosters was low and there is now widespread doubt amongst those who had the vaccine that they did the right thing, while there is both pride and vindication amongst those who didn't.In a world awash with both censorship and misinformation (which is worse? - there is another thing I'm not sure about), it is difficult to know who or what to believe.We do, however, have price. There is a truth to price. Price, like the truth, can change every day, many times per day, but the price of something, or should I say the price of a publicly traded asset, reflects all the available information about that asset at any given moment. In that respect, there is a truth to price.The price of Brent Crude Oil, currently $84, reflects all the available information there is about current and future oil supply, current and future demand, current and future government policy, net zero, global risk appetite and more. All the information, opinion, and research, the truths, the half-truths and the lies, the ideals and the realities - everything is distilled into those two digits: 84 dollars.And so today, with all this in mind, I thought it would be informative to ask - how are the vaccine stocks doing? How're they are doing might tell us about the vaccine narrative itself.Covid-19 vaccine stocks The main vaccine stocks are as follows: * Pfizer (NYSE: PFE) - although not a “pure” play (its share price is determined by the success or failure of many of its products and patents), it did bring the world's most famous and controversial vaccine to market. * Biotechnology company BioNTech (NASDAQ: BNTX), which teamed with Pfizer to produce its vaccine, can be seen as much more of a “vaccine bellwether” stock. Its messenger RNA (mRNA) technology was critical to the Pfizer vaccine.* Moderna (NASDAQ: MRNA). The ticker's on brand! Moderna was quick in the wake of Pfizer and BioNTech to win a US EUA for its vaccine. Unlike Pfizer and BioNTech, it doesn't have to split profits. It's also a ‘pure play”, so a good bellwether.* Johnson & Johnson's (NYSE: JNJ) sold its vaccine at cost during the pandemic and it is so diversified with numerous other products that we can probably discount it as a vaccine bellwether. Still, we can include it on the list as it is a key player.* Likewise AstraZeneca (LON: AZN) -was an early winner in the vaccine race, but then it got embroiled in disputes with the European Union. Like Johnson and Johnson, it is also heavily diversified with other products and it also initially delivered the vaccines at cost. So, again, it is not a “pure play.”* There is the lesser-known Novavax (NASDAQ: NVAX), whose product is not as widespread as the others.* Ocugen (NASDAQ: OCGN), also not very well known, is partnered with Indian drugco, Bharat Biotech, and has a vaccine authorised in India. * Finally, Vaxart (NASDAQ: VXRT), is developing an oral vaccination tablet. At this stage of writing this article, I haven't yet looked at a single chart of a “vaxco”, so I don't know what I'm about to discover. I'm going to post 4-year charts - ie going back a year before Covid - along with a 200-day moving average (200DMA) in green to help identify primary trends.Let's start with Pfizer (NYSE: PFE)You can see the run it had since 2020. But, shorter term, since early December, it's been falling like a boulder off a cliff. It's not seen any of the rally that accompanied the broader stock market since Christmas. It's below its 200DMA and trending down. On the other hand, it's still at $43, above its October low, and well above its pre-Covid price in the low- to mid-$30s, so all is not lost. I do not like the look of that chart at all. I'm pretty sure its handle will no longer be a four but a three before long.Next is BioNTech (NASDAQ: BNTX). This is a classic pop-and-drop and could just as easily be the chart of some crypto currency or junior miner.At $140, it's 70% down from its $460 high, and it too is in a downtrend. There is support at $120 and it's still three or four times higher than it was before Covid. I wish I'd known about BioNTech in 2020!Moderna (NASDAQ: MRNA) is next and like BioNTech, the other “pure vax play,” this is another pop-and-drop. Cynics would say pump and dump.Gosh, this was a $25 stock in 2020. It went to $500. How fortunes can change.Now it's at $175, 65% of its highs, but above its 200DMA. The shorter-term trend is down, however.Gosh, these vaxco stocks are volatile. As volatile as crypto. (I don't see the FCA warning against them, or indeed banning them though).Johnson & Johnson's (NYSE: JNJ) is next. Like Pfizer, it's not a pure play, but I do not like the look of this chart at all. Double tops and stuff.It's come down hard in 2023. What does the market know that I don't?It's below its 200DMA and trending lower. You want to see that October 2022 low, just around $158, holding, or failing that $152.To be fair to Johnson and Johnson, and not wanting to get too sensationalist, it has previous when it comes to spiky, up-and-down action. See early 2022 for more details.And so to AstraZeneca (LON: AZN) and this too could be displaying the worrying, early 2023 chart sickness of the vaccine major. Not as bad as the other two though.I'm going to give this one the benefit of the doubt and say it's a standard pullback to the 200DMA, which is rising, amidst an ongoing secular bull market.Pre-Covid it was around 7,000p, so it's about 45% up on the back of the pandemic.If they've banned cryptocurrencies, why the FCA hasn't banned speculating in the likes of Novavax (NASDAQ: NVAX), I cannot understand. Where's the consistency? Surely that is what we want from our regulators. In any case, this is one brutal chart, and it's back where it was before Covid.This was a $3 stock at the beginning of 2020. It went to $330. Somebody made a lot of money. Nancy Pelosi is my guess. Or maybe that Fauci bloke. (For the avoidance of legal doubt, I'm joking).Now it's a $10 stock. I make that a 97% drop. Somebody lost a lot of money.By the way, here's a chart of Novavax since its IPO in 1995. I don't think I've ever seen anything like it. Talk about hype cycles. Fortunes have been made and lost in this company over and over. Remind me to buy it in about a year's time at $5. It'll be $150 or $300 a couple of years after that. (Then remind me to sell it).Next, we have Ocugen (NASDAQ: OCGN). Cripes, it's another one. From a buck to 18 bucks back to a buck. I need to get more into biotech. It's extraordinary.And last up, Vaxart (NASDAQ: VXRT) is developing an oral vaccination tablet. I almost don't need to post this one. You know what's coming.From below a dollar to $25 back to a dollar - and trending lower.So what can we learn from all this?One: vaccines are dead in the water.Two: there might be something nasty lurking in the pipeline for Pfizer, and perhaps Johnson and Johnson. My guess is something legal.If you're buying gold, my current recommended bullion dealer in the UK is The Pure Gold Company, whether you are taking delivery or storing online. Premiums are low, quality of service is high. You can deal with a human being. I have an affiliation deals with them.If you're buying bitcoin, be sure to read my special report.And make your Number One resolution for 2023 to listen to Kisses on a Postcard.This article first appeared at Moneyweek. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

There has been a discernible change in the narrative over the past few weeks regarding Covid-19 vaccines. From the Andrew Bridgen affair and questions in the House of Commons regarding the unusually high seasonal death rates to the publicity that came with “Novacc” Djokovic winning the Australian Open, to the sudden collapse of Thailand's Princess Bajrakitiyabha, daughter of the King, and the resulting (likely fabricated) story that Thailand is nullifying its Pfizer contracts, the powers-that-be - and I'm still not sure who they actually are - seem to have lost control of the narrative.The take-up of boosters was low and there is now widespread doubt amongst those who had the vaccine that they did the right thing, while there is both pride and vindication amongst those who didn't.In a world awash with both censorship and misinformation (which is worse? - there is another thing I'm not sure about), it is difficult to know who or what to believe.We do, however, have price. There is a truth to price. Price, like the truth, can change every day, many times per day, but the price of something, or should I say the price of a publicly traded asset, reflects all the available information about that asset at any given moment. In that respect, there is a truth to price.The price of Brent Crude Oil, currently $84, reflects all the available information there is about current and future oil supply, current and future demand, current and future government policy, net zero, global risk appetite and more. All the information, opinion, and research, the truths, the half-truths and the lies, the ideals and the realities - everything is distilled into those two digits: 84 dollars.And so today, with all this in mind, I thought it would be informative to ask - how are the vaccine stocks doing? How're they are doing might tell us about the vaccine narrative itself.Covid-19 vaccine stocks The main vaccine stocks are as follows: * Pfizer (NYSE: PFE) - although not a “pure” play (its share price is determined by the success or failure of many of its products and patents), it did bring the world's most famous and controversial vaccine to market. * Biotechnology company BioNTech (NASDAQ: BNTX), which teamed with Pfizer to produce its vaccine, can be seen as much more of a “vaccine bellwether” stock. Its messenger RNA (mRNA) technology was critical to the Pfizer vaccine.* Moderna (NASDAQ: MRNA). The ticker's on brand! Moderna was quick in the wake of Pfizer and BioNTech to win a US EUA for its vaccine. Unlike Pfizer and BioNTech, it doesn't have to split profits. It's also a ‘pure play”, so a good bellwether.* Johnson & Johnson's (NYSE: JNJ) sold its vaccine at cost during the pandemic and it is so diversified with numerous other products that we can probably discount it as a vaccine bellwether. Still, we can include it on the list as it is a key player.* Likewise AstraZeneca (LON: AZN) -was an early winner in the vaccine race, but then it got embroiled in disputes with the European Union. Like Johnson and Johnson, it is also heavily diversified with other products and it also initially delivered the vaccines at cost. So, again, it is not a “pure play.”* There is the lesser-known Novavax (NASDAQ: NVAX), whose product is not as widespread as the others.* Ocugen (NASDAQ: OCGN), also not very well known, is partnered with Indian drugco, Bharat Biotech, and has a vaccine authorised in India. * Finally, Vaxart (NASDAQ: VXRT), is developing an oral vaccination tablet. At this stage of writing this article, I haven't yet looked at a single chart of a “vaxco”, so I don't know what I'm about to discover. I'm going to post 4-year charts - ie going back a year before Covid - along with a 200-day moving average (200DMA) in green to help identify primary trends.Let's start with Pfizer (NYSE: PFE)You can see the run it had since 2020. But, shorter term, since early December, it's been falling like a boulder off a cliff. It's not seen any of the rally that accompanied the broader stock market since Christmas. It's below its 200DMA and trending down. On the other hand, it's still at $43, above its October low, and well above its pre-Covid price in the low- to mid-$30s, so all is not lost. I do not like the look of that chart at all. I'm pretty sure its handle will no longer be a four but a three before long.Next is BioNTech (NASDAQ: BNTX). This is a classic pop-and-drop and could just as easily be the chart of some crypto currency or junior miner.At $140, it's 70% down from its $460 high, and it too is in a downtrend. There is support at $120 and it's still three or four times higher than it was before Covid. I wish I'd known about BioNTech in 2020!Moderna (NASDAQ: MRNA) is next and like BioNTech, the other “pure vax play,” this is another pop-and-drop. Cynics would say pump and dump.Gosh, this was a $25 stock in 2020. It went to $500. How fortunes can change.Now it's at $175, 65% of its highs, but above its 200DMA. The shorter-term trend is down, however.Gosh, these vaxco stocks are volatile. As volatile as crypto. (I don't see the FCA warning against them, or indeed banning them though).Johnson & Johnson's (NYSE: JNJ) is next. Like Pfizer, it's not a pure play, but I do not like the look of this chart at all. Double tops and stuff.It's come down hard in 2023. What does the market know that I don't?It's below its 200DMA and trending lower. You want to see that October 2022 low, just around $158, holding, or failing that $152.To be fair to Johnson and Johnson, and not wanting to get too sensationalist, it has previous when it comes to spiky, up-and-down action. See early 2022 for more details.And so to AstraZeneca (LON: AZN) and this too could be displaying the worrying, early 2023 chart sickness of the vaccine major. Not as bad as the other two though.I'm going to give this one the benefit of the doubt and say it's a standard pullback to the 200DMA, which is rising, amidst an ongoing secular bull market.Pre-Covid it was around 7,000p, so it's about 45% up on the back of the pandemic.If they've banned cryptocurrencies, why the FCA hasn't banned speculating in the likes of Novavax (NASDAQ: NVAX), I cannot understand. Where's the consistency? Surely that is what we want from our regulators. In any case, this is one brutal chart, and it's back where it was before Covid.This was a $3 stock at the beginning of 2020. It went to $330. Somebody made a lot of money. Nancy Pelosi is my guess. Or maybe that Fauci bloke. (For the avoidance of legal doubt, I'm joking).Now it's a $10 stock. I make that a 97% drop. Somebody lost a lot of money.By the way, here's a chart of Novavax since its IPO in 1995. I don't think I've ever seen anything like it. Talk about hype cycles. Fortunes have been made and lost in this company over and over. Remind me to buy it in about a year's time at $5. It'll be $150 or $300 a couple of years after that. (Then remind me to sell it).Next, we have Ocugen (NASDAQ: OCGN). Cripes, it's another one. From a buck to 18 bucks back to a buck. I need to get more into biotech. It's extraordinary.And last up, Vaxart (NASDAQ: VXRT) is developing an oral vaccination tablet. I almost don't need to post this one. You know what's coming.From below a dollar to $25 back to a dollar - and trending lower.So what can we learn from all this?One: vaccines are dead in the water.Two: there might be something nasty lurking in the pipeline for Pfizer, and perhaps Johnson and Johnson. My guess is something legal.If you're buying gold, my current recommended bullion dealer in the UK is The Pure Gold Company, whether you are taking delivery or storing online. Premiums are low, quality of service is high. You can deal with a human being. I have an affiliation deals with them.If you're buying bitcoin, be sure to read my special report.And make your Number One resolution for 2023 to listen to Kisses on a Postcard.This article first appeared at Moneyweek. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

Somewhere in May last year, when the second wave of pandemic was in the full swing, India was struggling to vaccinate its people. The government and vaccine makers were trading charges while Covid-19 was taking a heavy toll on human lives. India, which was home to the world's largest producer of Covid-19 vaccine, failed to inoculate the entire population during the course of that lethal wave. But a few months on, by the month of July, India became the only country after China to administer over two billion Covid vaccination doses. The vaccination drive, on scale, was hailed as one of the best in the world. So far, over 98% of adults have received at least one dose of the Covid vaccine, while 90% have been fully vaccinated. Nearly 22.7 million doses are available with states as of October 1. And just about 15 months later -- by the end of September -- over 100 million doses of vaccines ended up being wasted as their shelf life expired. Were there no takers of these booster doses or they simply didn't reach the needy? The loss, pegged at Rs 2,250 crore, fades in front of the loss it may have cost to people's health as the world is still facing acute vaccine inequality. The shelf life of Covishield is currently nine months, while that of Covaxin is 12 months. The shelf lives of both the vaccines were extended by three months last year. Non-Covid vaccines typically have a shelf life of three years. Why were 100 million doses wasted? As the pandemic waned, people became complacent. Masks disappeared from public places and there were few takers for booster doses. Over 84% of India's population is eligible for booster dose, but only 27% of them have received the shot. The booster coverage improved, thanks to a 75-day free booster dose campaign by the Centre. In mid-July, the booster dose coverage was at a meagre 8%. Despite the gains, India still has a long way to go in improving booster coverage. Had it not been the free booster dose campaign, the wastage would have been higher. In an interaction with Business Standard earlier, Adar Poonawalla indicated that he was trying to save around 50-100 million doses of vaccines in a free booster dose drive. Some amount of vaccine wastage is inevitable with such a large vaccination drive, however, governments try to minimise the damage. For all vaccines, GAVI recommends countries to keep the maximum wastage of 25% for the first year, with gradual reduction to 15% by the third year. For Covid vaccines, GAVI assumed the wastage rate could be 10%. If we look at the global scenario, the number of Covid-19 vaccines which are likely to have been wasted since the global roll out began is estimated to be 1.1 billion as of mid-July, according to data analytics firm Airfinity. “While wastage at any level is undesirable, it is the result of unprecedented vaccine production which has saved millions of lives. If we want a fast reacting global vaccine response system, we will have to accept some level of wasted doses,” says Airfinity CEO, Rasmus Bech. The other major reason why so many doses ended up being wasted in India was because of mis-anticipation of demand. Experts say companies were unclear about the purchase orders from the Centre and ramped up capacity in a big way. Serum had accumulated 250 million doses of formulated vaccines, and another 250 million in the bulk form by December last year and stopped Covishield production. Bharat Biotech too had a stock of 50 million doses lying at its plants around April and had halted production of Covaxin. The restrictions on exports did not help either. As India grappled with a deadly second wave in April last year, the government halted vaccine exports and resumed only towards the later end of the year. The restrictions meant that vaccine makers might have missed out on some of the export orders.  Prof Y K Gupta, member of the National Expert Group on Vaccine Administration for Covid-19, tells more Prof Y K Gupta, For

În cadrul ediției de pe 13 septembrie 2022 a emisiunii #știința360 de pe Radio România Cultural, Dr. Marius Geantă, Președintele Centrului pentru Inovație în Medicină #inomed, a comentat topul săptămânal Esențial Covid-19 de pe Raportuldegardă.ro. Pe 4 septembrie, China a anunțat aprobarea unui vaccin cu administrare inhalatorie, iar pe 6 septembrie, India a anunțat aprobarea unui alt vaccin sub formă de picături nazale. Aceste vaccinuri acționează asupra mucoaselor de la nivelul nasului, cavității bucale și plămânilor. Prin asigurarea imunității la poarta de intrare, vaccinurile cu administrare intranazală/intraorală ar putea să prevină chiar și cazurile ușoare de boală COVID-19 și să blocheze transmiterea către alte persoane. Vaccinul din China, dezvoltat de CanSino Biologics, conține aceleași ingrediente ca și vaccinul anti-COVID-19 al companiei. care este deja autorizat în țară. Un dispozitiv numit nebulizator transformă vaccinul lichid într-un spray cu aerosoli care este inhalat. Departamentul de sănătate din China și Administrația Națională a Produselor Medicale au aprobat ca vaccinul să fie utilizat ca doză de rapel. Noul vaccin din India, dezvoltat de Bharat Biotech, este aprobat pentru o schemă de vaccinare primară cu două doze. Peste 100 de astfel de vaccinuri sunt în curs de dezvoltare la nivel global, iar aproximativ 20 au ajuns în studii clinice. Mai multe detalii - https://bit.ly/3eTVsLN

The Union Ministry of Health (MoH) approved Bharat Biotech's Covid-19 nasal vaccine, Incovacc, for emergency use in India on Tuesday. Union health minister Mansukh Mandaviya announced the development on Twitter. With this, India will no longer have to depend only on the intramuscular shots that were hitherto available. But what are nasal vaccines? There are several methods of administering a vaccine. The most common is the intramuscular vaccine, where the shot is delivered into the muscle. In subcutaneous vaccines, the shot is delivered between the skin and the muscles. Vaccines may also be delivered orally, as in the case of Polio drops. However, in nasal vaccines, the shot is sprayed into the nostrils and inhaled. Several viruses enter the human body through the mucosa. These tissues line the nose, mouth, lungs, and digestive tract. When it enters the body, the immune cells get activated and flock to the site of infection to stop its spread. In the case of nasal vaccines, the virus may be stopped from entering the body by attacking it at its point of entry. How do vaccines work? When a vaccine is administered to a human body, the B cells in the blood start churning out antibodies. The most important of these are called IgG antibodies. They search for the virus in the body and, with the help of T cells, destroy the infected cells. How do nasal vaccines work? B cells, however, also reside around the mucosal tissues. When a nasal vaccine is administered, they form another type of antibody, IgA. IgA with T cells destroys the pathogens in the airway only. Also, they memorise the pathogen and prevent it from entering the body ever again. How is a nasal vaccine better than the usual ones? There are three main reasons why nasal vaccines are better than intramuscular ones. First, these vaccines reduce the administration cost as they do not need syringes and needles. Second, Nasal vaccines can be easily self-administered. They do away with the dependence on trained individuals. Third, as the virus is not allowed to enter the body, the symptoms, if any, are mild. How will Bharat Biotech's nasal vaccine be administered? Bharat Biotech's Incovacc will have a two-dose schedule. The first dose would involve a total of 4 drops with 2 in each nostril. The second dose will have to be repeated within 28 days. This second dose would also involve a total of 4 drops, 2 in each nostril.

Vaccines such as iNCOVACC can prevent mild cases of Covid and break the line of transmission of the disease.

India and China have cleared separate needle-free Covid vaccines, one a spray in the nose and the other inhaled through the mouth, Associated Press reported yesterday. Regulators in India have authorized Bharat Biotech's nasal version as an option for people who haven't yet been vaccinated. Apple's September iPhone event is later today and its priciest smartphone yet is expected. Notes: India and China have cleared separate needle-free Covid vaccines, one a spray in the nose and the other inhaled through the mouth, Associated Press reported yesterday. Regulators in India authorized Bharat Biotech's nasal version on Tuesday as an option for people who haven't yet been vaccinated. “This step will further strengthen our collective fight against the pandemic,” India's health minister Mansukh Mandaviya said on Twitter. Bharat Biotech hasn't yet released the results of its studies or details on when the vaccine will be available on the market, according to AP. Meanwhile, in China, CanSino Biologics announced on Sunday last that Chinese regulators have approved an inhalable version of the company's vaccine – to be used as a booster dose. The company pointed to preliminary results of studies suggesting the inhaled version improved immune protection after one puff, but it's not clear if it also increases effectiveness, according to AP. Apple's annual September iPhone event – which the company has tagged with the phrase ‘far out' – is expected later today. Four new iPhones, three new Apple Watches, and a new AirPods Pro model are expected, according to various media reports. Apple is likely to raise the price of the high-end iPhone Pro that Apple trackers are expecting to arrive with a major camera upgrade and an ‘always on' display. The company's latest software, iOS 16, is also expected soon. On the services front, Apple is jumping into the buy-now-pay-later market, with its Apple Pay Later product. Apple is also doubling its ad business team, according to the Financial Times. China aims to accelerate the autonomous cars ecosystem in the country. The port city of Shanghai, one of China's biggest industrial and commercial centres, estimates that autonomous cars and related technologies can produce 500 billion yuan ($72 billion) in economic value by 2025, South China Morning Post reported yesterday. A new plan, released by the General Office of Shanghai Municipal People's Government, on Monday, calls for establishing an ecosystem that is self-reliant concerning R&D and core technologies related to autonomous vehicles, according to SCMP. Reliance Industries has entered into definitive agreements for acquiring a 79.4 percent stake of SenseHawk, through primary infusion and secondary purchase, for a total consideration of $32 million, the Indian conglomerate told the stock exchanges in Mumbai in a filing yesterday. SenseHawk, founded in 2018, is an early-stage California-based developer of software-based management tools for the solar energy generation industry. Theme music courtesy Free Music & Sounds: https://soundcloud.com/freemusicandsounds

In celebration of 75 years of Independence, Prime Minister Narendra Modi announced free booster doses at government vaccination centres for 75 days from July 15 to September 30, 2022. A few days after this announcement, the news website The Wire published a shocking story on how the Central Drug Standards Control Organisation - the CDSCO - the country's drug regulatory agency- never approved of precautionary doses. In this episode, we speak to Banjot Kaur, the reporter who broke this important story this July. Early this year, a Telangana court asked The Wire to take down several articles related to vaccine policy based on a defamation suit by Bharat Biotech, which manufactures Covaxin. One of these stories pulled down was Banjot's story. She has been writing on science and public health for 12 years, and has worked at Down to Earth Magazine and Times of India. References PM Modi's address to the nationExclusive: Nobody Approved India's ‘Precautionary' Doses – The Wire SciencePress briefing on the actions taken, preparedness and updates on COVID-19, Dated: 24.12.202110 Questions the Indian Govt Must Answer About Vaccines for Minors and BoostersDCGI clears Bharat Biotech, SII COVID-19 vaccines but efficacy question unansweredhttps://www.sunoindia.in/the-suno-india-show/why-a-covaxin-controversy-in-bhopal-is-worrying-trial-participants-activists-and-experts/See sunoindia.in/privacy-policy for privacy information.

India's drug regulator on Tuesday approved the emergency use of two Covid-19 vaccines, Biological E's Corbevax and Bharat Biotech's Covaxin, for children under the age of 12 years – a milestone move that paves the way for that cohort in the country to receive a vaccine shot against the disease for the first time. Tune in with the executive editor of Hindustan Times Sachin Kalbag and RJ Rohini to know more about this news.

This week, we're joined by Abhishek Mohan, Founder and CEO of Hempstreet - India's first research to retail venture in the Ayurvedic cannabis sector. We explore attitudes towards the medical use of cannabis within India, and how it currently fits into the framework of traditional Indian Ayurvedic medicine.  

In this episode, Farheen Khan discusses the implementation of crypto tax regulations in India, as well as the government's stated intention to make crypto legal only after global consensus. She also discusses the recent issues surrounding Bharat Biotech's Covaxin. The vaccine manufacturer, according to the WHO, needs to upgrade its production plants. And sadly, a new covid-19 variant has been discovered in the UK. Make sure to tune in to not miss out on important updates!

Indian mainstream media tends to see our country with the gaze of a privileged North Indian man. That is changing. Dhanya Rajendran joins Amit Varma in episode 267 of The Seen and the Unseen to talk about her journey in setting up The News Minute, and in deepening our journalism and the conversations we have. Also check out: 1. Dhanya Rajendran on Twitter, Instagram and The News Minute. 2. Support The News Minute. 3. Cut the Clutter. 4. The Life and Times of Abhinandan Sekhri -- Episode 254 of The Seen and the Unseen. 5. The death of Savita Halappanavar. 6. Steven Van Zandt: Springsteen, the death of rock and Van Morrison on Covid — Richard Purden. 7. Some regional publications: Newsmeter, The Cue and Truecopythink. 8. 7 Indians are hostages in a conflict between Houthi rebels and Saudi coalition in Yemen -- Sanyukta Dharmadhikari. 9. The Story of an Income Tax Search -- Dhanya Rajendran on Instagram. 10. TV Newsance -- Manisha Pande -- YouTube Playlist. 11. 10,000 people charged with sedition in one Jharkhand district -- Supriya Sharma for Scroll. 12. Manju and the Mommy Wars: Why should women conform to 'ideal mother' stereotype? -- Sowmya Rajendran. 13. Superforecasting -- Philip Tetlock and Dan Gardner. 14. The Mallu Analyst on YouTube. 15. Get Roast with Gaya3 on YouTube. 16. A Meditation on Form -- Amit Varma. 17. Narendra Modi takes a Great Leap Backwards -- Amit Varma on Demonetisation. 18. Ram Guha Reflects on His Life -- Episode 266 of The Seen and the Unseen. 19. Tweets on the Bharat Biotech court case by Siddharth Varadarajan and Dhanya Rajendran. (See who got trolled more!) 20. Does India take its national symbols too seriously? — Jan 2008 episode of We the People. 21. Our Hindu Rashtra -- Aakar Patel. 22. Price of the Modi Years -- Aakar Patel. 23. Whole Numbers and Half Truths -- Rukmini S. 24. Rukmini Sees India's Multitudes -- Episode 261 of The Seen and the Unseen (w Rukmini S). 25. Malare -- Song from Premam. 26. Missing: Half the Story: Journalism as if Gender Matters -- Kalpana Sharma and others. 27. The Anatomy of Hate -- Revati Laul. 28. The Seasons of Trouble -- Rohini Mohan. 29. Notting Hill. 30. And once again, support The News Minute! This episode is sponsored by CTQ Compounds. Check out The Daily Reader and FutureStack. Use the code UNSEEN for Rs 2500 off. Check out Amit's online course, The Art of Clear Writing. And subscribe to The India Uncut Newsletter. It's free!

On today's episode, Manaswini discusses the Covaxin crisis. As children aged between 15 and 18 become eligible for Covid-19 vaccinations, there is a lot of confusion. Why? The lack of transparency behind Bharat Biotech's Covaxin's expiry date extensions. In other news, she highlights Tesla's achievements over the last year. Musk appears to have a lot to look forward to in the year 2022.

Ocugen's founder and CEO Shankar Musunuri speaks to Scrip about his company's mutation-agnostic gene therapy candidate OCU-400, a commercial agreement with CanSino Biologics and plans for a bridging study of partner Bharat Biotech's COVID-19 vaccine Covaxin post a US FDA clinical hold.

Founder of Bharat Biotech says that the covid-19 pandemic will become an endemic by mid-2022. The official from the manufacturers of Covaxin added that a Covid-19 reinfection is possible, as the vaccines will only protect the bottom part of your lungs, reducing the risks of hospitalisation or death.

The threat of a fresh Covid-19 variant is looming large and half of the country's population is yet to be fully vaccinated. Adding to the woes, Pune-based Serum Institute of India has now announced that it will reduce the production of the Oxford-Astra­Ze­neca vaccine, marketed as Covishield in India, by at least 50 per cent from next week. The vaccine maker says that it does not have fresh orders from the Indian government. And if we factor in the possibility of a booster dose, then the vaccine shortfall could only increase. Let us see how much stock we are left with and what is the road ahead.  Serum CEO Adar Poonawalla said that the company has about 500 million doses of Covishield left in stock. And half of it is in an unfinished state. Poonawalla said SII will start exporting the available stock if the Indian government doesn't need the supply. And on Tuesday, the government told the Parliament that 227.6 million doses were available with the states as on December 1, 2021. A Business Standard analysis shows that the government, on December 1, did not have enough doses to administer a second jab to people who have not been fully vaccinated and vaccinate the remaining unvaccinated individuals. Of the 36 states and UTs for which data is available, only 11 states had enough doses to cover their partially vaccinated population with a second dose and the unvaccinated people with first doses. Uttar Pradesh, for instance, had a shortfall of 67.7 million doses, while Maharashtra and Bihar were short of over 25 million doses each, as on December 1, 2021. Tamil Nadu and West Bengal were short of nearly 20 million doses during the period. Serum Institute of India's 500 million doses of Covishield -- if they have been prioritised for the Indian government--plus the stock of Covaxin with Bharat Biotech, should be enough to fulfill India's vaccination requirements for the adult population.  However, if India goes for an additional dose for the fully vaccinated population or a booster dose, then there might be a shortfall. This shortfall in vaccines is particularly telling when we still don't know how the Omicron variant of coronavirus will act up. Medical experts and epidemiologists have warned that Covid-19 will become endemic and people will require annual booster shots. And India is yet to take a final call on vaccinating children. Given all these uncertainties, the country cannot afford disruption in supply of vaccines. Watch video

Organisasi Kesehatan Dunia (WHO) menyetujui penggunaan darurat vaksin Covid-19 produksi Bharat Biotech, India. Rombongan Universitas Gadjah Mada kecelakaan di Tol Cipali-Cikampek Km 113, Kamis (4/11/2021) sekitar pukul 02.00 WIB. Polisi belum melakukan penahanan pada Rachel Vennya yang sudah ditetapkan sebagai tersangka.

4 de noviembre | Nueva YorkHola, maricoper. Ayer lanzamos maricope.store, nuestra tienda oficial con hasta nueve productos: sudaderas, camisetas, pegatinas y hasta una cantimplora. Llevamos meses debatiendo sobre nuestros diseños favoritos y ahora te toca a ti valorar si hemos acertado, jeje. El póster maricoper estará disponible únicamente a lo largo de este jueves, así que no dejes pasar mucho tiempo si lo quieres en tu habitación.Bienvenido a La Wikly diaria, una columna de actualidad y dos titulares rápidos para pasar el resto del día bien informado. Si quieres comentar las noticias en nuestra comunidad privada de Discord, puedes entrar rellenando este formulario. Y si te han enviado esta newsletter, puedes suscribirte aquí:El podcast de La Wikly también está disponible en iTunes, Spotify y iVoox.* Añade el podcast a tu plataforma favorita haciendo click en el botón “Listen in podcast app” que aparece justo debajo del reproductor.Leer esta newsletter te llevará 6 minutos y 8 segundos.Cada vez que leo algo sobre los maricopers. Bienvenido a La Wikly.⚠️ Democrats in disarrayPor Emilio DoménechLo importante: las derrotas demócratas en Virginia hicieron saltar las alarmas en Washington D.C., desatando una serie de narrativas que prometen dividir lo suficiente al partido como para asegurar su hundimiento en las elecciones del año que viene.Explícamelo: el viraje generalizado del electorado de Virginia hacia los republicanos, uno que ya comenté por encima en la columna de ayer, es un adelanto de lo que podría ser una estrategia ganadora en las midterms de 2022, cuando los demócratas se jugarán sus mayorías en las cámaras legislativas.Contexto: los demócratas tienen ahora mayorías muy breves en la Cámara de Representantes, donde solo cinco escaños netos le quitarían el poder a Nancy Pelosi; y el Senado, donde solo un escaño neto será suficiente para devolverle a Mitch McConnell el liderazgo de la cámara.* Perder la cámara alta en 2022, especialmente si en 2024 los republicanos tienen un buen año, podría significar que los demócratas no la recuperen hasta 2028, allanando el terreno para que el partido conservador asiente su poder durante décadas.Esta narrativa es sin duda apocalíptica para los demócratas, pero responde a una preocupación constante entre activistas: perder el Senado puede significar no poder poner a un juez progresista en el Tribunal Supremo hasta finales de la década, cuando el obstruccionismo republicano pueda desaparecer.* Y Stephen Breyer, uno de los tres progresistas de la corte de nueve jueces, tiene 83 años.Además, los republicanos siguen afianzando su poder en aquellos estados en los que controlan la redistribución de distritos. Algo que es especialmente al nivel de distritos estatales, esos que les permiten asegurar sus mayorías legislativas durante generaciones.* En 2010, la ola republicana contra Barack Obama posibilitó que los republicanos dibujaran los mapas en estados como Wisconsin, Michigan o Pennsylvania. Ahora mismo, los demócratas tienen imposible ganar mayorías allí incluso en años de ola azul como 2018.* Es un círculo vicioso:Si controlas las cámaras legislativas estatales, controlas la redistribución de distritos. Si controlas la redistribución de distritos, aseguras que nunca pierdes el control de las cámaras legislativas estatales.Los demócratas tienen pocas opciones de revancha porque apenas controlan la redistribución de distritos salvo que en estados como Nueva York, Illinois y Maryland, con lo que sus opciones para contrarrestar el gerrymandering republicano siempre se va a limitar a esas lides.* Y si no contrarrestan con suficientes distritos favorables, los republicanos podrán seguir gobernando como un partido de la minoría.* (Algo que ya sucede de forma mucho más bestia en el Senado, una cámara donde están representadas las zonas rurales de forma desproporcionada).Con ese panorama, establishment e izquierda demócratas se lanzan dardos con tal de echarse la culpa sobre las derrotas en Virginia (y el susto en Nueva Jersey). Y ninguno de los bandos tiene información suficiente como para saber qué funcionará en la próxima cita electoral.* ¿Es un mensaje moderado que no pida subir los impuestos? ¿Son políticas progresistas que planteen una reimaginación del papel del gobierno en la vida pública?Nada está claro, pero lo que sí es evidente es que Biden está arrastrando a su partido a una debacle en 2022 que podría ser definitiva para el futuro del partido en la próxima década. Y quizá con consecuencias irresolubles sobre la democracia en EE. UU.Más información en The Daily Kos.

In this episode, find out about why WHO has sought clarifications from Bharat Biotech, also find out why Kotak Mahindra bank's net profit fell in Q2 Business Term of the Day: Provision coverage ratio

- Chính phủ Ấn Độ đang thận trọng trong việc phê duyệt giấy phép sử dụng khẩn cấp với vaccine ngừa Covid-19 Cô-va-xin (Covaxin) dành cho trẻ em do công ty dược nội địa Bơ-ha-rát Bai-ô-tếch (Bharat Biotech) nghiên cứu, phát triển. Tác giả : Phan Tùng/VOV Ấn Độ Chủ đề : ấn độ, vaccine, trẻ em --- Support this podcast: https://anchor.fm/vov1thegioi/support

With about 29% of India's population fully vaccinated, the government's Subject Expert Committee (SEC) has now recommended Bharat Biotech's COVID-19 vaccine, Covaxin, for Emergency Use Authorisation (EUA) for children aged 2-18 years. This is the second vaccine in India to be cleared for children. Earlier, Zydus Cadilla's vaccine got authorization for kids above 12. While the timeline for the supply of Covaxin for children is still unclear, its availability as an option has raised some critical questions: Is it really necessary to expose children to a vaccine authorised for emergency use, when it is evident that they only contract a mild infection and don't face the threat of mortality? Secondly, is WHO clearance for Covaxin a mere formality or should it be a matter of concern that a vaccine that is yet to get WHO clearance for adults has already got approval for children in India? We explore these issues in this episode. Guest: Jacob Koshy, Deputy Science Editor at The Hindu Host: G. Sampath, Social Affairs Editor, The Hindu

In big news in India's vaccination drive, the Subject Expert Committee (SEC) recommended to the Drug Controller General of India (DCGI) to grant emergency use authorisation for Bharat Biotech's Covaxin for children as young as two years. On 12 October, the expert panel in a statement said that “after detailed deliberation, the committee recommended for grant of market authorisation of the vaccine for the age group of 2 to 17 years for restricted use in an emergency.” This announcement makes Covaxin the second vaccine after Zydus Cadila's ZyCoV-D DNA based vaccine, to be approved for vaccinating those under the age of 18, and the first vaccine in the world to be approved for children below the age of 12. Though DCGI has not given the formal nod yet, the lack of publicly available data regarding the clinical trials and the fact that Covaxin has still not been approved by the World Health Organisation has raised some concerns with health experts on how effective the vaccine will be on children. What also does not help Bharat Biotech's case is its previous lack of transparency about the conduct of Covaxin clinical trials in adults and how it reported adverse side effects. And this brings up the pertinent questions on every parents mind-how safe is Covaxin for children? How many doses should be administered? And do children already affected with COVID-19 need the vaccine? Host and Producer: Himmat Shaligram Guest: Dr Gagandeep Kang, a renowned virologist with CMC Vellore and a member of the National Technical Advisory Group on Immunisation (NTAGI) Editor: Shelly Walia Music: Big Bang Fuzz Listen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur To help us answer these questions, for today's episode we spoke to Dr Gagandeep Kang, a renowned virologist with CMC Vellore and a member of the COVID-19 World Group the National Technical Advisory Group on Immunisation.

Central governments' Covid-19 subject expert committee has approved the Bharat Biotech's Covaxin vaccine for emergency use. To know about this, tune in as Rohini and Sachin share everything with their listeners.

The Indian benchmark indices ended a volatile day in the positive territory with the BSE Sensex closing above the 60,000 level. The 30-pack index rose 149 points to 60,284. The Nifty50, meanwhile, was slightly below the 18,000-mark at 17,992, up 46 points. Titan Company, Bajaj Auto, Bajaj Finserv, SBI and Hindalco were among the major gainers on the Nifty. HCL Technologies, HDFC Life,  Coal India, Tech Mahindra and Shree Cement were among the big losers. About 1,664 shares have advanced, 1,483 shares declined, indicating the breadth remains in favour of bulls. On the sectoral front, auto, FMCG, metal and PSU Bank indices rose 1-3 percent, while the IT index lost nearly 1 percent. The Nifty IT index extended losses for the second day post TCS' earnings. Meanwhile, the broader markets too ended in the green. The BSE Smallcap was up 0.14 per cent, while the Midcap index ended 0.65 per cent higher. The domestic indices managed to end on a positive note while global markets traded with cuts in fears of rising inflation due to soaring commodity prices and energy crunch. Oil price rose towards $84 a barrel supported by a rebound in global demand that is contributing to energy shortages in big economies such as China. Coming to stock-specific moves, shares of Radico Khaitan zoomed 14 per cent following the launch of two new luxury products in the brown and white spirit categories. Lupin's stock ended with gains of 1 per cent after getting the approval for clinical trial of Remdesivir powder. Metal names too gained in the second half of the day with Hindalco and Vedanta closing at day's high. Further, Consumption discretionary stock Titan hit record high today ahead of the festive season, crossing the Rs 2,500-mark. That said, the stock of HCL Technologies was the top Nifty loser ahead of its earnings on October 14. Meanwhile, Bharat Biotech's COVID-19 vaccine, Covaxin, has received emergency use authorisation  for children aged 2-18 years. The SEC has submitted its recommendation to the Drugs Controller General of India (DCGI) for final approval. Going into trade on Wednesday, the markets will take cues from the September CPI inflation and August industrial output data besides companies' earnings for the quarter ended September. All eyes will be on Wipro, Infosys and Mindtree, which will announce their Q2 numbers on October 13. Lastly, global markets, stock-specific moves as well as news related to Covid-19 will be among other major triggers for investors.

Empresa intermediou aquisição de doses da Covaxin entre o Ministério da Saúde e a farmacêutica Bharat Biotech.

Atualizações sobre o caso da compra da vacina indiana Covaxin: a Justiça retirou o sigilo de documentos sobre a compra da vacina. Além disso, o Governo rescindiu o contrato com a fabricante Bharat Biotech para compra do imunizante. Saiba os detalhes com o monitor do curso de jornalismo, Caio Mello.

VOV1 - Biến thể Delta của vi-rút SARS Cov-2 đang tàn phá thế giới với tốc độ chưa từng có, và mọi việc đều đang nằm ngoài dự tính của con người. Vấn đề là thế giới cần phải có chiến lược vaccine sáng tạo hơn, quyết đoán hơn nhằm ngăn chặn đà lây nhiễm của SARS-CoV-2. Với lợi thế về dân số và khoa học công nghệ, Ấn Độ là quốc gia đang tiến hành nghiên cứu, thử nghiệm và phát triển các sản phẩm mới nhằm ngăn chặn Covid-19. Trong quá trình này, Việt Nam là một trong các quốc gia đối tác trong việc nghiên cứu, thử nghiệm các loại vaccine được sản xuất từ Ấn Độ. Phóng viên Phan Tùng - Thường trú Đài TNVN tại Ấn Độ phỏng vấn Tiến sỹ Krishna Ella, Chủ tịch Công ty Dược Ấn Độ Bharat Biotech – nhà sản xuất vaccine Covaxin ngừa Covid-19 làm rõ hơn những nội dung này. Chủ đề : Ấn Độ, ngăn chặn Covid-19 --- Support this podcast: https://anchor.fm/vov1thegioi/support

O senador Ciro Nogueira (PP-PI) disse à CNN (https://bit.ly/3xb2W0w) que tem um encontro marcado com o presidente Jair Bolsonaro (sem partido) nesta segunda-feira (26) para tratar sobre sua provável indicação ao cargo de ministro-chefe da Casa Civil. A expectativa é de que Bolsonaro anuncie as mudanças da sua equipe ministerial propostas na semana passada após a conversa. Com a troca, o atual titular da pasta, Luiz Eduardo Ramos, deve se tornar chefe da Secretaria-Geral da Presidência no lugar de Onyx Lorenzoni. Outra notícia da emissora (https://bit.ly/3y7TY5f) ressalta que o Ministério da Saúde notificou a Precisa Medicamentos no domingo (25) sobre o cancelamento do contrato para compra de 20 milhões de doses da Covaxin. A rescisão aconteceu após o laboratório indiano Bharat Biotech, que fabrica a vacina, informar na semana passada que a empresa não a representava mais no Brasil por adulteração em documentos entregues ao governo federal. Investigada na CPI da Covid, a Precisa nega qualquer adulteração. Falando em CPI da Covid, as suspeitas na compra de vacinas serão o centro dos debates no retorno da comissão em agosto, após o recesso parlamentar. Segundo o G1 (https://glo.bo/2VehUoT), em calendário prévio definido pela cúpula no domingo (25), o reverendo Amilton Gomes será ouvido no dia 3 de agosto. Ele teria sido autorizado pelo Executivo a negociar doses da AstraZeneca com a Davati Medical Supply. Também no domingo, o presidente da CPI, senador Omar Aziz (PSD-AM), anunciou que quer ouvir o Facebook, o Twitter e o Google sobre veiculação de fake news em meio à pandemia, reforça o UOL (https://bit.ly/2Tz4zam).

A Bharat Biotech informou que rescindiu um memorando de entendimento para vender a vacina Covaxin para a Precisa Medicamentos. O monitor Caio Mello (do curso de Jornalismo) traz detalhes sobre o comunicado enviado pela fabricante indiana e as denúncias pelas quais a empresa intermediadora em questão está envolvida. Além disso, ele conta o que o governador João Doria (PSDB) falou, em entrevista à CBN, a respeito da possibilidade de reduzir o intervalo entre as duas doses da Pfizer e AstraZeneca, do novo ciclo de vacinação contra Covid-19 em 2022 e da flexibilização das medidas restritivas no estado de São Paulo em agosto.

O laboratório indiano Bharat Biotech, fabricante da Covaxim, nega que tenha enviado documentos apresentados pela brasileira Precisa ao Ministério da Saúde e por isso resolveu romper contrato.

Senadores da CPI da Covid se irritaram hoje com o silêncio da diretora técnica da Precisa Medicamentos, Emanuela Medrades e suspenderam o depoimento. A empresa — que representa no Brasil a Bharat Biotech, fabricante da vacina Covaxin — é citada como intermediária nas negociações para compra do imunizante indiano. Ontem, o presidente do Supremo Tribunal Federal, ministro Luiz Fux, concedeu à Emanuela habeas corpus que permite a ela ficar em silêncio diante dos questionamentos dos senadores.  André Mendonça, chefe da Advocacia-Geral da União (AGU), foi indicado formalmente pelo presidente Jair Bolsonaro para assumir a vaga deixada por Marco Aurélio Mello no Supremo Tribunal Federal (STF). A indicação consta na edição do Diário Oficial da União (DOU) desta terça-feira, 13.  E mais: governo federal exclui Inpe da divulgação dos dados sobre alertas de incêndios e queimadas no Brasil. Ouça estas e outras notícias desta terça-feira, 13, no “Eldorado Expresso”. See omnystudio.com/listener for privacy information.

Pesquisa realizada pela Confederação Nacional do Transporte (CNT) em parceria com o Instituto MDA entre 1º e 3 de julho aponta que a avaliação positiva do governo Jair Bolsonaro (quando o entrevistado diz considerar a gestão ótima ou boa) caiu de 33%, em fevereiro de 2020, para 27,7% em julho deste ano. A queda levou a aprovação para o pior patamar desde o início da atual gestão, em janeiro de 2019. Integrantes da CPI da Covid no Senado vão investigar a elevação do preço das doses da vacina Covaxin nas negociações entre o Ministério da Saúde e as empresas Bharat Biotech e Precisa Medicamentos. Governo destina R$ 2,1 bilhões para Saúde via orçamento secreto. E ainda: Anvisa propõe suspender a vacinação de grávidas com imunizantes da Janssen e AstraZeneca. Ouça estas e outras notícias desta segunda-feira, dia 5, no “Eldorado Expresso”. See omnystudio.com/listener for privacy information.

There was a time when we got vaccinated and never knew the name of the company on the label, and never asked. But today, Covishield vs. Covaxin is like Shah Rukh vs. Amir Khan or Apple vs. Android. To many, criticism of Covaxin is anti-national. For others, Covaxin is as effective as right wing propaganda. The truth, as usual, is hostage to polarizing narratives and political messaging. A day after Bharat Biotech released Covaxin phase 3 results as a pre-print, with peer review and YouTube comments pending, we delve into the topic. Your hosts: Kanishka Chatterjee (KC) & Sharath C George (SCG). --- Send in a voice message: https://podcasters.spotify.com/pod/show/the-viral-truth/message

In this latest SBS Hindi News bulletin of Australia and India: New South Wales records 35 new cases, the Premier says the Sydney lockdown is working; European Commission says the Indian -manufactured doses of AstraZeneca, made by Covishield, have not been approved by the European Union regulator; In India, Bharat Biotech claims Covaxin is 65.2% efficient against Delta variant of Covid-19 and more news.

Indian cricket team in Sri Lanka could finally start training ahead of the limited-overs series, Bharat Biotech releases Covaxin Phase-3 trial data and claims 77.8% efficacy, Aamir Khan and Kiran Rao announce divorce after 15years of marriage and other top stories in your bulletin.

Na semana em que uma massa de ar frio congelou estados do Sul e Sudeste do Brasil, a temperatura sobe em Brasília por conta dos desdobramentos da CPI da Pandemia. Na sexta passada, o deputado Luis Miranda (DEM-DF) e seu irmão, Luis Ricardo Miranda, servidor de carreira do Ministério da Saúde, contam os detalhes de uma manobra para a compra da vacina indiana Covaxin, com preço 1.000% acima do inicialmente informado pelo laboratório indiano Bharat Biotech. A negociação, que era do conhecimento do Presidente Bolsonaro, era intermediada pela Precisa Medicamentos, cujo dono, o empresário Francisco Maximiano, tem ligações pessoais com o senador Flávio Bolsonaro, filho do presidente. Além disso, surgiu ainda, na terça feira, uma nova denúncia sobre um pedido propina de US$ 1 por dose na compra de vacinas por meio da Davaty Medical Supply. A compra de 400 milhões de doses do imunizante geraria uma propina de aproximadamente R$ 2 bilhões. Enquanto isso, na capital paulista, o movimento Coalizão pela Vida lançou a Aliança Parlamentar contra a COVID-19 e, para contar um pouco mais a respeito do movimento, o Conexão Internacional dessa semana recebe Fábio Paes, Diretor de Desenvolvimento Institucional e Advocacy do SEFRAS. Já fora do país, os casos de covid aumentam na Austrália e o Canadá sofre com a onda de calor e cora de vergonha com a descoberta de mais sepulturas clandestinas de crianças indígenas. . O programa Conexão Internacional é apresentado por Marco Antonio Rossi, e conta com as participações de Rosana Dias (Toronto - Canadá), Maria Luiza Abbott (Londres - Reino Unido), José Gabriel Andrade (Lisboa - Portugal) e Santiago Farrell (Buenos Aires - Argentina). É veiculado todas as sextas, às 15h, com reapresentações aos sábados, às 10h, e aos domingos, também às 10h, na Rádio Mega Brasil Online e é disponibilizado, simultaneamente com a estreia, em imagens na TV Mega Brasil.

Na coluna Direto de Brasília desta sexta-feira, 02, Eliane Cantanhêde comenta andamento da CPI. Após dar um “passo em falso” na convocação do policial militar Luiz Paulo Dominghetti Pereira, a CPI da Covid deve voltar aos trilhos na próxima semana e retomar a investigação da denúncia de corrupção na compra da Covaxin, vacina fabricada pela farmacêutica indiana Bharat Biotech. Essa é a análise da jornalista Eliane Cantanhêde no novo episódio de Por Dentro da CPI. Eliane Cantanhêde ainda trata de outros assuntos e responde a perguntas de ouvintes. Ela conversa ao vivo com Haisem Abaki e Carolina Ercolin, no Jornal Eldorado, da Rádio Eldorado (FM 107,3), de segunda a sexta, das 9h às 9h30.  See omnystudio.com/listener for privacy information.

Na coluna Direto de Brasília desta sexta-feira, 02, Eliane Cantanhêde comenta andamento da CPI. Após dar um “passo em falso” na convocação do policial militar Luiz Paulo Dominghetti Pereira, a CPI da Covid deve voltar aos trilhos na próxima semana e retomar a investigação da denúncia de corrupção na compra da Covaxin, vacina fabricada pela farmacêutica indiana Bharat Biotech. Essa é a análise da jornalista Eliane Cantanhêde no novo episódio de Por Dentro da CPI. Eliane Cantanhêde ainda trata de outros assuntos e responde a perguntas de ouvintes. Ela conversa ao vivo com Haisem Abaki e Carolina Ercolin, no Jornal Eldorado, da Rádio Eldorado (FM 107,3), de segunda a sexta, das 9h às 9h30.  See omnystudio.com/listener for privacy information.

No podcast ‘Notícia No Seu Tempo', confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S. Paulo' desta quarta-feira (30/06/21): Um dia após Jair Bolsonaro ser alvo de notícia-crime encaminhada por senadores ao STF, acusado de prevaricação, o Ministério da Saúde suspendeu o contrato para a compra de 20 milhões de doses da vacina indiana Covaxin, por R$ 1,6 bilhão. O governo age para esvaziar suspeitas de que a compra do imunizante envolveria um esquema de corrupção com o conhecimento do presidente, enquanto prepara a contraofensiva na CPI da Covid.  E mais: Economia: Taxa na conta de luz sobe 52% e outro reajuste já está previsto Metrópole: Governos dão prêmio para atrair à 2ª dose de vacina Internacional: Onda de calor mata ao menos 34 no Canadá Na Quarentena: Projeto une artistas e moradores de rua para arrecadar doações See omnystudio.com/listener for privacy information.

Nos últimos dias, o relato do parlamentar Luis Miranda  (DEM-DF), e de e seu irmão Luís Ricardo Fernandes Miranda, que é servidor do Ministério da Saúde, atearam fogo no debate sobre irregularidades na compra da vacina indiana Covaxin. Segundo documentos do Ministério das Relações Exteriores, o governo comprou o imunizante por um preço 1.000% maior do que era anunciado pela própria fabricante seis meses antes. O deputado ainda garante que avisou à presidência da República sobre o caso.  A vacina produzida pela Bharat Biotech tinha o preço estimado em US$ 1,34 a dose. Em fevereiro deste ano, o Ministério da Saúde pagou US$ 15 por unidade, a mais cara das seis vacinas compradas até agora. O acordo da Covaxin previa o fornecimento de 6 milhões de unidades já em março, mas condicionava a um aval da Anvisa, que só foi dado no dia 4 deste mês. Segundo o deputado Luis Miranda, a denúncia foi apresentada para Bolsonaro com provas e relata ter ouvido uma promessa de que a Polícia Federal iria investigar o caso. Em depoimento ao Ministério Público Federal seu irmão, Luís Ricardo afirmou ter recebido "pressões anormais" para a aquisição da Covaxin, o que não ocorreu em relação a outras vacinas. O Ministério Público Federal, que investiga suspeitas envolvendo a compra do imunizante, afirmou ver indícios de crime e “interesses divorciados do interesse público” na contratação. Um dos investigados é Francisco Emerson Maximiano, proprietário de empresas do ramo farmacêutico, uma delas é a Precisa, que em janeiro deste ano havia se tornado a única representante no País da Bharat Biotech, fabricante indiana da Covaxin. No episódio de hoje, quem nos explica toda essa história que envolve o imunizante da Covaxin e a suspeita de irregularidades é a repórter do Estadão, em Brasília, Camila Turtelli. Também vamos falar sobre o potencial explosivo que essa denúncia tem para o governo com o cientista político e diretor-executivo da Transparência Brasil, Manoel Galdino. O Estadão Notícias está disponível noSpotify,Deezer,Apple Podcasts,Google Podcasts, ou no agregador de podcasts de sua preferência. Apresentação: Emanuel Bomfim e Larissa Burchard Produção/Edição: Gustavo Lopes, Julia Corá, Ana Paula Niederauer, Jefferson Perleberg e Larissa Burchard. Sonorização/Montagem: Moacir Biasi See omnystudio.com/listener for privacy information.

O Ministério da Saúde assinou no dia 25 de fevereiro um contrato para a compra de 20 milhões de doses da vacina Covaxin, produzida pelo laboratório indiano Bharat Biotech. O acordo entrou na mira da CPI da Covid no Senado e do Ministério Público Federal por suspeitas de irregularidades. Em depoimento ao Ministério Público em março, o chefe de importação do Departamento de Logística do Ministério da Saúde, Luis Ricardo Fernandes Miranda, apontou “pressões anormais” para a aquisição da Covaxin. E ainda: o estresse de profissionais de psicologia que também precisam de ajuda na pandemia. Ouça essas e outras notícias desta quinta-feira, 24, no “Eldorado Expresso”.  See omnystudio.com/listener for privacy information.

Against the backdrop of India's punishing second wave of COVID-19, Dr. Raches Ella of Bharat Biotech joins the podcast to talk about the company's pioneering work in vaccines. He discusses their own COVID-19 vaccine, Covaxin, the challenges India faces right now in administering vaccine to such a large population, and Bharat's innovative work in developing a respiratory vaccine to fight a respiratory virus.Takeaways:04:07 — When the virus hit, Bharat Biotech were well placed to respond. The result is Covaxin.09:58 — Just how effective are the vaccines against the COVID-19 variants of concern?15:30 — 20 million doses of Covaxin have been administered in India. While all production is currently mandated for domestic use, the only way out of the pandemic is equitable distribution of vaccine globally.18:36 — India leveraged its childhood vaccination program to roll out the COVID-19 vaccine.20:15 — As a country with high levels of infectious diseases, vaccine hesitancy is not really an issue in India.22:53 — Respiratory vaccine for a respiratory virus: Bharat Biotech have partnered with Washington University in St. Louis to develop an intranasal vaccine. Currently in trials and hoping for release by the end of this year.26:12 — What can the world do right now to help India? A great start would be standardized protocols for treating and managing COVID-19 from the WHO.31:10 — Beyond COVID-19: Bharat Biotech are also working on vaccines for polio, cholera and chikungunya.Special guest:Raches Ella, MBBS, MS, Head of Business Development & Advocacy and Project Lead for Sars COV2 vaccine 

Recorded February 24, 2021Current Episodes at https://walkinverse.buzzsprout.com/I am moving all podcast here slowly. I will keep buzzsprout for all public reports and here for member only content.Report #38, "Big Pharma Experiment: mRNA Injection."In this report, we will dig into the connection between Big Pharma and the push behind the dangerous mRNA backed by facts—adverse reactions and death seen around the globe.Grab a pen and notebook and enjoy the report.E-Book ReportWIV Reports — Uncensored is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Report References* 2 people in India die after receiving Covid jab as Bharat Biotech says vaccine too risky for some [Internet]. RT International. 2021 [cited 2021 Jan 19]. Available from: https://www.rt.com/news/512914-india-deaths-covid-vaccine/* Tom Ozimek. 4 Oregonians Test Positive for COVID-19 After 2nd Vaccine Dose [Internet]. www.theepochtimes.com. 2021 [cited 2021 Feb 16]. Available from: https://www.theepochtimes.com/4-oregonians-test-positive-for-covid-19-after-2nd-vaccine-dose_3697172.html* N/A. 7 die at Spanish care home after getting Pfizer Covid-19 jab as ALL residents test positive for virus, second doses still to come [Internet]. RT International. 2021 [cited 2021 Feb 1]. Available from: https://www.rt.com/news/514303-deaths-pfizer-vaccine-covid-spain/* 10 dead in Germany within 4 days of Covid-19 vaccine inoculation; probe ordered [Internet]. Republic World. 2021 [cited 2021 Feb 16]. Available from: https://www.republicworld.com/world-news/europe/10-dead-in-germany-within-4-days-of-covid-19-vaccine-inoculation-probe-ordered.html* N/A. 10 Dead with 51 Severe Side-Effects Among Germany's Elderly after Experimental Pfizer COVID Injections [Internet]. Health Impact News. 2021 [cited 2021 Jan 19]. Available from: https://healthimpactnews.com/2021/10-dead-with-51-severe-side-effects-among-germanys-elderly-after-experimental-pfizer-covid-injections/* N/A. 13 Israelis suffer FACIAL PARALYSIS after taking Pfizer Covid jab, amid influx of reports detailing adverse effects [Internet]. RT International. 2021 [cited 2021 Jan 17]. Available from: https://www.rt.com/news/512736-israel-facial-paralysis-13-covid-vaccine/* 18 U.S. Code § 241 - Conspiracy against rights [Internet]. LII / Legal Information Institute. [cited 2021 Feb 15]. Available from: https://www.law.cornell.edu/uscode/text/18/241* Senior MK. 21 people experienced anaphylaxis after receiving Pfizer's vaccine [Internet]. Mail Online. 2021 [cited 2021 Feb 16]. Available from: https://www.dailymail.co.uk/health/article-9119029/At-21-Americans-life-threatening-anaphylaxis-receiving-Pfizers-vaccine-CDC-reveals.html* 28-Year-old Wisconsin Healthcare Worker has Aneurysm – Brain Dead Five Days After Second Experimental Pfizer mRNA COVID Injection [Internet]. Vaccine Impact. 2021 [cited 2021 Feb 16]. Available from: https://vaccineimpact.com/2021/28-year-old-wisconsin-healthcare-worker-has-aneurysm-brain-dead-five-days-after-second-experimental-pfizer-mrna-covid-injection/* Brian Shilhavy. 39-Year-Old Medical Doctor and Son of Former Chief Justice of Trinidad Found Dead After COVID Injection in Ireland [Internet]. Medical Kidnap. 2021 [cited 2021 Feb 16]. Available from: https://medicalkidnap.com/2021/02/08/39-year-old-medical-doctor-and-son-of-former-chief-justice-of-trinidad-found-dead-after-covid-injection-in-ireland/* Patrick Delaney. 39-year-old nurse aide dies ‘within 48 hours' of receiving mandated COVID-19 shot [Internet]. LifeSiteNews. 2021 [cited 2021 Jan 28]. Available from: https://www.lifesitenews.com/news/39-year-old-nurse-aide-dies-within-48-hours-of-receiving-mandated-covid-19-shot* 45-Year-Old Italian Doctor “In the Prime of Life and in Perfect Health” Drops Dead After the Pfizer mRNA COVID Shot: 39-Year-Old Nurse, 42-Year-Old Surgical Technician Also Dead [Internet]. Health Impact News. 2021 [cited 2021 Feb 5]. Available from: https://healthimpactnews.com/2021/45-year-old-italian-doctor-in-the-prime-of-life-and-in-perfect-health-drops-dead-after-the-pfizer-mrna-covid-shot-39-year-old-nurse-42-year-old-surgical-technician-also-dead/* 46-year old healthcare worker dies day after receiving COVID-19 vaccine; govt says death not related to jab [Internet]. 2021 [cited 2021 Feb 16]. Available from: https://www.businesstoday.in/current/economy-politics/46-year-old-healthcare-worker-dies-day-after-receiving-covid-19-vaccine-govt-says-death-not-related-to-jab/story/428280.html* 58-Year-Old Mother and Grandmother of Six in Virginia Dies Within Hours of Receiving Experimental Pfizer mRNA Injection [Internet]. Health Impact News. 2021 [cited 2021 Feb 5]. Available from: https://healthimpactnews.com/2021/58-year-old-mother-and-grandmother-of-six-in-virginia-dies-within-hours-of-receiving-experimental-pfizer-mrna-injection/* 75-year-old Israeli woman found lifeless hours after second dose of Covid-19 vaccine [Internet]. Israel National News. 2021 [cited 2021 Feb 16]. Available from: https://www.israelnationalnews.com/News/News.aspx/294861* Capar R-I. 82-year-old resident at Sola nursing home dies one day after being vaccinated against COVID-19 [Internet]. Norway Today. 2021 [cited 2021 Feb 16]. Available from: https://norwaytoday.info/news/82-year-old-resident-at-sola-nursing-home-dies-one-day-after-being-vaccinated-against-covid-19/* Brian Shilhavy. 181 Dead in the U.S. During 2 Week Period From Experimental COVID Injections – How Long Will We Continue to Allow Mass Murder by Lethal Injection? [Internet]. Health Impact News. 2021 [cited 2021 Jan 25]. Available from: https://healthimpactnews.com/2021/181-dead-in-the-u-s-during-2-week-period-from-experimental-covid-injections-how-long-will-we-continue-to-allow-mass-murder-by-lethal-injection/* Adam Dick. A Nursing Home had Zero Coronavirus Deaths. Then, It Vaccinates Residents for Coronavirus and the Deaths Begin. [Internet]. 2021 [cited 2021 Jan 11]. Available from: http://www.ronpaulinstitute.org/archives/peace-and-prosperity/2021/january/10/a-nursing-home-had-zero-coronavirus-deaths-then-it-vaccinates-residents-for-coronavirus-and-the-deaths-begin/* Dineshwori L. AIIMS' security guard admitted to ICU post Covid-19 vaccination [Internet]. 2021 [cited 2021 Feb 16]. Available from: https://www.thehealthsite.com/news/adverse-events-post-covid-19-vaccination-aiims-security-guard-admitted-to-icu-791480/* Kovacs J. American dies hours after COVID vaccine [Internet]. WND. 2021 [cited 2021 Jan 26]. Available from: https://www.wnd.com/2021/01/californian-dies-hours-covid-vaccine/* AstraZeneca, Bharat Biotech Vaccines Nab Emergency Approval in India [Internet]. GeneOnline News. 2021 [cited 2021 Feb 21]. Available from: https://geneonline.news/en/astrazeneca-bharat-biotech-vaccines-nab-emergency-approval-in-india/* Basingstoke care home records 22 deaths in three weeks in one of UK's worst Covid-19 outbreaks [Internet]. Daily Echo. 2021 [cited 2021 Feb 1]. Available from: https://www.dailyecho.co.uk/news/19043944.coronavirus-outbreak-22-deaths-pemberley-house-care-home/* BUSTED: CDC Inflated COVID Numbers, Accused of Violating Federal Law [Internet]. National File. 2021 [cited 2021 Feb 16]. Available from: https://nationalfile.com/busted-cdc-inflated-covid-numbers-accused-of-violating-federal-law/* Corrupt Science and Elite Power: Your Techno-Slavery is Now Imminent [Internet]. The Columbus Freepress. 2020 [cited 2021 Feb 20]. Available from: https://freepress.org/article/corrupt-science-and-elite-power-your-techno-slavery-now-imminent* Caceres M. Courts in Spain Order Forced COVID-19 Vaccination of Incapacitated Nursing Home Residents [Internet]. The Vaccine Reaction. 2021 [cited 2021 Feb 22]. Available from: https://thevaccinereaction.org/2021/02/courts-in-spain-order-forced-covid-19-vaccination-of-incapacitated-nursing-home-residents/* Jane Roberts. COVID immune response suspected in young doctor's death [Internet]. Memphis Local, Sports, Business & Food News | Daily Memphian. 2021 [cited 2021 Feb 16]. Available from: https://dailymemphian.com/article/19893/surgeon-died-of-suspected-delayed-immune-response* AG C. CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force [Internet]. GlobeNewswire News Room. 2020 [cited 2021 Feb 19]. Available from: http://www.globenewswire.com/news-release/2020/03/02/1993888/0/en/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavirus-Task-Force.html* Dozens of people develop rare blood disorder after taking coronavirus vaccines – reports [Internet]. RT International. 2021 [cited 2021 Feb 16]. Available from: https://www.rt.com/usa/515157-covid-vaccine-side-effects-blood/* Dr. David Mukanga visits the Paul-Ehrlich-Institut [Internet]. Global Health Protection Programme. 2018 [cited 2021 Feb 19]. Available from: https://ghpp.de/en/projects/regtrain-vacctrain/dr-david-mukanga-visits-the-paul-ehrlich-institut/* Europe still wary of AstraZeneca Covid-19 vaccine as Dutch scientific advisers recommend limiting jab to under-65s [Internet]. RT International. [cited 2021 Feb 5]. Available from: https://www.rt.com/news/514641-netherlands-astrazeneca-covid-vaccine-under65/* Floridians file hundreds of COVID-19 vaccine side effect reports [Internet]. WFTS. 2021 [cited 2021 Feb 16]. Available from: https://www.abcactionnews.com/news/state/floridians-file-hundreds-of-covid-19-vaccine-side-effect-reports* Former Detroit TV Anchor Karen Hudson-Samuels Dies One Day After Taking COVID Vaccine [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://detroit.cbslocal.com/2021/02/16/former-detroit-tv-anchor-dies-one-day-after-taking-covid-vaccine/* From the 2/4/2021 release of VAERS data [Internet]. 2021 [cited 2021 Feb 18]. Available from: https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=CAT&EVENTS=ON&VAX=COVID19* Tyler Durden. German Nursing Home Whistleblower: “Elderly Dying After COVID Vaccine” [Internet]. ZeroHedge. 2021 [cited 2021 Feb 16]. Available from: https://www.zerohedge.com/covid-19/german-nursing-home-whistleblower-elderly-dying-after-covid-vaccine* Danielle Haynes. Germany recommends AstraZeneca vaccine for only those under 65 [Internet]. UPI. 2021 [cited 2021 Jan 29]. Available from: https://www.upi.com/Top_News/World-News/2021/01/28/Germany-recommends-AstraZeneca-vaccine-for-only-those-under-65/7911611858574/* Gloucester resident dies within hours of receiving Pfizer vaccine [Internet]. WTKR. 2021 [cited 2021 Feb 16]. Available from: https://www.wtkr.com/news/gloucester-resident-dies-within-hours-of-receiving-pfizer-vaccine* Health care worker dies after second dose of COVID vaccine, investigations underway [Internet]. Orange County Register. 2021 [cited 2021 Feb 16]. Available from: https://www.ocregister.com/2021/01/26/health-care-worker-dies-after-second-dose-of-covid-vaccine-investigations-underway* Caceres M. Health Care Worker in Orange County, California Dies Four Days After Getting COVID-19 Vaccine [Internet]. The Vaccine Reaction. 2021 [cited 2021 Feb 16]. Available from: https://thevaccinereaction.org/2021/02/health-care-worker-in-orange-county-california-dies-four-days-after-getting-covid-19-vaccine/* Dave Urbanski. Health care worker taken to ER just a few hours after getting second COVID-19 vaccine shot. Four days later he was dead. [Internet]. TheBlaze. 2021 [cited 2021 Jan 29]. Available from: https://www.theblaze.com/news/health-care-worker-taken-to-er-just-a-few-hours-after-getting-second-covid-vaccine-shot-four-days-later-he-was-dead* M.d MN. How can this be?  All residents and staff vaccinated for Covid, then all test positive and 7 die, after zero prior cases [Internet]. Anthrax Vaccine -- posts by Meryl Nass, M.D. 2021 [cited 2021 Feb 5]. Available from: https://anthraxvaccine.blogspot.com/2021/02/how-can-this-be-all-residents-and-staff.html* HAF. Indian Hospital Worker Dies Just 24 Hours After Receiving COVID-19 Vaccine Covishield [Internet]. https://humansarefree.com/. 2021 [cited 2021 Jan 19]. Available from: https://humansarefree.com/2021/01/indian-hospital-worker-dies-just-24-hours-after-receiving-covid-19-vaccine-covishield.html/* N/A. Investigation launched as 2 people die in Norway nursing home days after receiving Pfizer's Covid-19 vaccine [Internet]. RT International. [cited 2021 Jan 5]. Available from: https://www.rt.com/news/511623-norway-covid19-vaccine-deaths/* Brown L. Israeli man reportedly dies of heart attack hours after getting COVID vaccine [Internet]. New York Post. 2020 [cited 2021 Jan 4]. Available from: https://nypost.com/2020/12/29/israeli-man-dies-of-heart-attack-after-getting-covid-vaccine/* Israel T, Pfizer. Israeli Teenager Hospitalized in ICU for “Inflammation of the Heart” Days after Receiving Second Pfizer Vaccine [Internet]. Health Impact News. 2021 [cited 2021 Feb 5]. Available from: https://healthimpactnews.com/2021/israeli-teenager-hospitalized-in-icu-for-inflammation-of-the-heart-days-after-receiving-second-pfizer-vaccine/* Man dies after receiving vaccination at Javits Center; doctor says initial indications show no allergic reaction [Internet]. News 12 - The Bronx. 2021 [cited 2021 Feb 16]. Available from: https://bronx.news12.com/man-dies-after-receiving-vaccination-at-javits-center-doctor-says-initial-indications-show-no-allergic-reaction* MAAYAN JAFFE-HOFFMAN. Man's fatal heart attack likely unlinked to vaccine he took hours before [Internet]. The Jerusalem Post | JPost.com. 2020 [cited 2021 Jan 4]. Available from: https://www.jpost.com/breaking-news/israel-nears-100000-coronavirus-vaccinations-per-day-goal-653461* Luke Webber. Marketing Authorisation: the goal of pharmaceutical regulatory affairs [Internet]. Proclinical. 2018 [cited 2021 Feb 19]. Available from: https://www.proclinical.com/blogs/2018-2/marketing-goal-of-pharmaceutical-regulatory-affairs* MHRA awarded over £980,000 for collaboration with the Bill and Melinda Gates Foundation and the World Health Organisation [Internet]. GOV.UK. 2017 [cited 2021 Feb 21]. Available from: https://www.gov.uk/government/news/mhra-awarded-over-980000-for-collaboration-with-the-bill-and-melinda-gates-foundation-and-the-world-health-organisation* MHRA Enters 3-Year Collaboration With Gates Foundation, WHO [Internet]. 2017 [cited 2021 Feb 21]. Available from: https://www.fdanews.com/articles/184777-mhra-enters-3-year-collaboration-with-gates-foundation-who* Mark Hodge. Nine care home residents killed in Covid outbreak six days after getting vaccine [Internet]. The Sun. 2021 [cited 2021 Feb 16]. Available from: https://www.thesun.co.uk/news/13926276/covid-deaths-care-home-spain/* Sandhya Srinivasan AJ& VJ. Nine health workers have died in vaccine rollout. India must disclose status of probe into each case [Internet]. Scroll.in. https://scroll.in; 2021 [cited 2021 Feb 16]. Available from: https://scroll.in/article/985273/nine-health-workers-have-died-in-vaccine-rollout-india-must-disclose-status-of-probe-into-each-case* Lars Erik Taraldsen, Naomi Kresge. Norway Warns of Vaccination Risks for Sick Patients Over 80. Bloomberg.com [Internet]. 2021 Jan 15 [cited 2021 Jan 29]; Available from: https://www.bloomberg.com/news/articles/2021-01-15/norway-warns-of-vaccination-risks-for-sick-patients-over-80* Capar R-I. Norwegian Medicines Agency links 13 deaths to vaccine side effects. Those who died were frail and old [Internet]. Norway Today. 2021 [cited 2021 Jan 29]. Available from: https://norwaytoday.info/news/norwegian-medicines-agency-links-13-deaths-to-vaccine-side-effects-those-who-died-were-frail-and-old/* N/A. Nuremberg Code: Directives for Human Experimentation [Internet]. The Office of Research Integrity. [cited 2020 May 20]. Available from: https://ori.hhs.gov/chapter-3-The-Protection-of-Human-Subjects-nuremberg-code-directives-human-experimentation* Davis A, Walker DG. On the Path to UHC – Global Evidence Must Go Local to Be Useful; Comment on “Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy.” International Journal of Health Policy and Management [Internet]. 2019 Mar 1 [cited 2021 Feb 21];8(3):181–3. Available from: https://www.ijhpm.com/article_3575.html* Robert Koch Institute [Internet]. Gates Foundation. 2019 [cited 2021 Feb 19]. Available from: https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2019/11/OPP1216026* N/A. Search Results from the VAERS Database [Internet]. 2020 [cited 2021 Feb 1]. Available from: https://medalerts.org/vaersdb/findfield.php?IDNUMBER=918034* Search Results from the VAERS Database [Internet]. 2021 [cited 2021 Feb 16]. Available from: https://medalerts.org/vaersdb/findfield.php?IDNUMBER=944595* Search Results from the VAERS Database [Internet]. [cited 2021 Feb 18]. Available from: https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=CAT&EVENTS=ON&VAX=COVID19&STATE=WI* Sirur S. Serum Institute ties up with Gates Foundation for 10 crore doses of Covid vaccine [Internet]. ThePrint. 2020 [cited 2021 Feb 21]. Available from: https://theprint.in/india/serum-institute-ties-up-with-gates-foundation-for-10-crore-doses-of-covid-vaccine/477133/* “Serum won't have to take full loss”: Bill Gates says his Foundation shares financial risk for vaccine [Internet]. MSN. 2020 [cited 2021 Feb 21]. Available from: https://www.msn.com/en-in/money/news/serum-won-t-have-to-take-full-loss-bill-gates-says-his-foundation-shares-financial-risk-for-vaccine/ar-BB1caHpL* SII has produced 40-50 mn dosages of Covishield [Internet]. 2020 [cited 2021 Feb 21]. Available from: http://news.rediff.com/commentary/2020/dec/28/sii-has-produced-4050-mn-dosages-of-covishield/90c66a232ef2d0be98aebceccca9e970* Staff K. South Dakota reports 2 deaths recorded after COVID-19 vaccinations [Internet]. https://www.blackhillsfox.com. 2021 [cited 2021 Feb 16]. Available from: https://www.blackhillsfox.com/2021/01/20/south-dakota-reports-2-deaths-recorded-after-covid-19-vaccinations/* HAF. Spain: Second Pfizer Shots Halted After 46 Nursing Home Residents Die After the First Shot [Internet]. https://humansarefree.com/. 2021 [cited 2021 Feb 19]. Available from: https://humansarefree.com/2021/02/spain-pfizer-shots-halted-after-46-nursing-home-residents-died.html/* Ido Efrati, Ronny Linder. Thousands of Israelis tested positive for coronavirus after first vaccine shot [Internet]. Haaretz.com. 2021 [cited 2021 Feb 1]. Available from: https://www.haaretz.com/israel-news/thousands-of-israelis-tested-positive-for-coronavirus-after-first-vaccine-shot-1.9462478* McFall-Johnsen M. UK watchdogs say people with learning disabilities have been given inappropriate “do not resuscitate” orders for COVID-19 [Internet]. Business Insider. 2020 [cited 2021 Feb 15]. Available from: https://www.businessinsider.com/uk-learning-disabilities-inappropriate-do-not-resuscitate-orders-2021-2* SPN. Un altro infermiere muore nel sonno. “Infarto”. Aveva fatto la seconda dose di vaccino [Internet]. Secondo Piano News. 2021 [cited 2021 Feb 22]. Available from: https://www.secondopianonews.it/news/cronaca/2021/01/27/un-altro-infermiere-muore-nel-sonno-infarto-aveva-fatto-la-seconda-dose-di-vaccino.html* VAERS_Table_of_Reportable_Events_Following_Vaccination.pdf [Internet]. [cited 2021 Feb 15]. Available from: https://vaers.hhs.gov/docs/VAERS_Table_of_Reportable_Events_Following_Vaccination.pdf* N/A. WHO Following Probe Into “23 Reported Deaths” in Norway After Pfizer Vaccine Injection [Internet]. 2021 [cited 2021 Jan 15]. Available from: https://sputniknews.com/amp/europe/202101151081777740-who-aware-of-23-reported-deaths-in-norway-after-pfizer-vaccination-seeks-to-follow-probe/* LifeSiteNews.com. World's biggest vaccine company sues COVID shot volunteer who spoke about negative side effects [Internet]. LifeSiteNews. 2020 [cited 2021 Feb 21]. Available from: https://www.lifesitenews.com/news/gates-foundation-backed-covid-vaccine-maker-sues-trial-volunteer-alleging-brain-damage* Young man develops “rare life-threatening syndrome” after Covid-19 vaccine [Internet]. Israel National News. 2021 [cited 2021 Feb 16]. Available from: https://www.israelnationalnews.com/News/News.aspx/294606 This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit walkinverse.substack.com/subscribe

Confira os destaques do caderno Metrópole do Estadão desta quarta-feira (13/01/21)See omnystudio.com/listener for privacy information.

Confira os destaques desta segunda-feira (23/11/20) no caderno Metrópole do EstadãoSee omnystudio.com/listener for privacy information.

It typically takes five years and about Rs 15 crore for just the first of many phases to introduce a viable vaccine to market. Companies across India such as Zydus Cadila, Serum Institute and Bharat Biotech are working against the clock to shrink this period down to a few months. Forbes India's Divya Shekhar takes a deep dive into what this rush looks like on the ground and gives us a glimpse into the path ahead in this episode